FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290851550> ?p ?o ?g. }

• W4290851550 endingPage "160" @default.
• W4290851550 startingPage "154" @default.
• W4290851550 abstract "Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy.In this randomised, double-blind, placebo-controlled, treatment-withdrawal, phase 3 trial, biologic-naïve patients (aged 2 to <18 years) with active disease were treated with open-label subcutaneous secukinumab (75/150 mg in patients <50/≥50 kg) in treatment period (TP) 1 up to week 12, and juvenile idiopathic arthritis (JIA) American College of Rheumatology 30 responders at week 12 were randomised 1:1 to secukinumab or placebo up to 100 weeks. Patients who flared in TP2 immediately entered open-label secukinumab TP3 that lasted up to week 104. Primary endpoint was time to disease flare in TP2.A total of 86 patients (median age, 14 years) entered open-label secukinumab in TP1. In TP2, responders (ERA, 44/52; JPsA, 31/34) received secukinumab or placebo. The study met its primary end point and demonstrated a statistically significant longer time to disease flare in TP2 for ERA and JPsA with secukinumab versus placebo (27% vs 55%, HR, 0.28; 95% CI 0.13 to 0.63; p<0.001). Exposure-adjusted incidence rates (per 100 patient-years (PY), 95% CI) for total patients were 290.7/100 PY (230.2 to 362.3) for adverse events and 8.2/100 PY (4.1 to 14.6) for serious adverse events in the overall JIA population.Secukinumab demonstrated significantly longer time to disease flare than placebo in children with ERA and JPsA with a consistent safety profile with the adult indications of psoriatic arthritis and axial spondyloarthritis.NCT03031782." @default.
• W4290851550 created "2022-08-12" @default.
• W4290851550 creator A5002868596 @default.
• W4290851550 creator A5006317525 @default.
• W4290851550 creator A5010382336 @default.
• W4290851550 creator A5010897332 @default.
• W4290851550 creator A5012015082 @default.
• W4290851550 creator A5015700716 @default.
• W4290851550 creator A5018961899 @default.
• W4290851550 creator A5020148707 @default.
• W4290851550 creator A5020603336 @default.
• W4290851550 creator A5021386589 @default.
• W4290851550 creator A5024754731 @default.
• W4290851550 creator A5027440653 @default.
• W4290851550 creator A5027612338 @default.
• W4290851550 creator A5040767751 @default.
• W4290851550 creator A5061885517 @default.
• W4290851550 creator A5062959400 @default.
• W4290851550 creator A5064302794 @default.
• W4290851550 creator A5068517463 @default.
• W4290851550 creator A5069622085 @default.
• W4290851550 creator A5079636331 @default.
• W4290851550 creator A5079883250 @default.
• W4290851550 creator A5080140512 @default.
• W4290851550 creator A5085125040 @default.
• W4290851550 date "2022-08-12" @default.
• W4290851550 modified "2023-10-15" @default.
• W4290851550 title "Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial" @default.
• W4290851550 cites W1483788981 @default.
• W4290851550 cites W1903167817 @default.
• W4290851550 cites W1935617463 @default.
• W4290851550 cites W1973354423 @default.
• W4290851550 cites W2043306063 @default.
• W4290851550 cites W2054276574 @default.
• W4290851550 cites W2073700972 @default.
• W4290851550 cites W2103524303 @default.
• W4290851550 cites W2106079991 @default.
• W4290851550 cites W2114155762 @default.
• W4290851550 cites W2138181327 @default.
• W4290851550 cites W2168029208 @default.
• W4290851550 cites W2278932593 @default.
• W4290851550 cites W2312982528 @default.
• W4290851550 cites W2529225914 @default.
• W4290851550 cites W2566483740 @default.
• W4290851550 cites W2584290672 @default.
• W4290851550 cites W2605851254 @default.
• W4290851550 cites W2745845806 @default.
• W4290851550 cites W2754740078 @default.
• W4290851550 cites W2795184644 @default.
• W4290851550 cites W2797862713 @default.
• W4290851550 cites W2895111641 @default.
• W4290851550 cites W2941230658 @default.
• W4290851550 cites W2985236937 @default.
• W4290851550 cites W3006821669 @default.
• W4290851550 cites W3034005436 @default.
• W4290851550 cites W3047978234 @default.
• W4290851550 cites W3087556346 @default.
• W4290851550 cites W3092915044 @default.
• W4290851550 cites W3112278337 @default.
• W4290851550 cites W3118393256 @default.
• W4290851550 cites W3192890697 @default.
• W4290851550 doi "https://doi.org/10.1136/ard-2022-222849" @default.
• W4290851550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35961761" @default.
• W4290851550 hasPublicationYear "2022" @default.
• W4290851550 type Work @default.
• W4290851550 citedByCount "19" @default.
• W4290851550 countsByYear W42908515502022 @default.
• W4290851550 countsByYear W42908515502023 @default.
• W4290851550 crossrefType "journal-article" @default.
• W4290851550 hasAuthorship W4290851550A5002868596 @default.
• W4290851550 hasAuthorship W4290851550A5006317525 @default.
• W4290851550 hasAuthorship W4290851550A5010382336 @default.
• W4290851550 hasAuthorship W4290851550A5010897332 @default.
• W4290851550 hasAuthorship W4290851550A5012015082 @default.
• W4290851550 hasAuthorship W4290851550A5015700716 @default.
• W4290851550 hasAuthorship W4290851550A5018961899 @default.
• W4290851550 hasAuthorship W4290851550A5020148707 @default.
• W4290851550 hasAuthorship W4290851550A5020603336 @default.
• W4290851550 hasAuthorship W4290851550A5021386589 @default.
• W4290851550 hasAuthorship W4290851550A5024754731 @default.
• W4290851550 hasAuthorship W4290851550A5027440653 @default.
• W4290851550 hasAuthorship W4290851550A5027612338 @default.
• W4290851550 hasAuthorship W4290851550A5040767751 @default.
• W4290851550 hasAuthorship W4290851550A5061885517 @default.
• W4290851550 hasAuthorship W4290851550A5062959400 @default.
• W4290851550 hasAuthorship W4290851550A5064302794 @default.
• W4290851550 hasAuthorship W4290851550A5068517463 @default.
• W4290851550 hasAuthorship W4290851550A5069622085 @default.
• W4290851550 hasAuthorship W4290851550A5079636331 @default.
• W4290851550 hasAuthorship W4290851550A5079883250 @default.
• W4290851550 hasAuthorship W4290851550A5080140512 @default.
• W4290851550 hasAuthorship W4290851550A5085125040 @default.
• W4290851550 hasBestOaLocation W42908515501 @default.
• W4290851550 hasConcept C126322002 @default.
• W4290851550 hasConcept C142724271 @default.
• W4290851550 hasConcept C197934379 @default.
• W4290851550 hasConcept C198451711 @default.
• W4290851550 hasConcept C203092338 @default.

• next